Structure Therapeutics Statistics
Total Valuation
GPCR has a market cap or net worth of $3.09 billion. The enterprise value is $1.65 billion.
Important Dates
The next estimated earnings date is Friday, May 8, 2026, after market close.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GPCR has 70.84 million shares outstanding. The number of shares has increased by 12.46% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 70.84M |
| Shares Change (YoY) | +12.46% |
| Shares Change (QoQ) | +8.38% |
| Owned by Insiders (%) | 3.56% |
| Owned by Institutions (%) | 80.85% |
| Float | 54.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.03 |
| P/TBV Ratio | 2.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.81, with a Debt / Equity ratio of 0.00.
| Current Ratio | 24.81 |
| Quick Ratio | 24.43 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -11.86% and return on invested capital (ROIC) is -9.76%.
| Return on Equity (ROE) | -11.86% |
| Return on Assets (ROA) | -9.39% |
| Return on Invested Capital (ROIC) | -9.76% |
| Return on Capital Employed (ROCE) | -12.28% |
| Weighted Average Cost of Capital (WACC) | -2.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$641,827 |
| Employee Count | 220 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GPCR has paid $515,000 in taxes.
| Income Tax | 515,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +83.49% in the last 52 weeks. The beta is -1.25, so GPCR's price volatility has been lower than the market average.
| Beta (5Y) | -1.25 |
| 52-Week Price Change | +83.49% |
| 50-Day Moving Average | 54.92 |
| 200-Day Moving Average | 44.34 |
| Relative Strength Index (RSI) | 31.09 |
| Average Volume (20 Days) | 957,332 |
Short Selling Information
The latest short interest is 6.15 million, so 8.68% of the outstanding shares have been sold short.
| Short Interest | 6.15M |
| Short Previous Month | 5.76M |
| Short % of Shares Out | 8.68% |
| Short % of Float | 11.21% |
| Short Ratio (days to cover) | 5.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -186.81M |
| Pretax Income | -140.69M |
| Net Income | -141.20M |
| EBITDA | -185.13M |
| EBIT | -186.81M |
| Earnings Per Share (EPS) | -$2.39 |
Full Income StatementBalance Sheet
The company has $1.45 billion in cash and $6.49 million in debt, giving a net cash position of $1.44 billion or $20.32 per share.
| Cash & Cash Equivalents | 1.45B |
| Total Debt | 6.49M |
| Net Cash | 1.44B |
| Net Cash Per Share | $20.32 |
| Equity (Book Value) | 1.52B |
| Book Value Per Share | 21.41 |
| Working Capital | 1.51B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$222.20 million and capital expenditures -$3.61 million, giving a free cash flow of -$225.81 million.
| Operating Cash Flow | -222.20M |
| Capital Expenditures | -3.61M |
| Depreciation & Amortization | 1.68M |
| Net Borrowing | n/a |
| Free Cash Flow | -225.81M |
| FCF Per Share | -$3.19 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |